FERRO, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 503
AS - Asia 217
EU - Europa 165
SA - Sud America 57
AF - Africa 32
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 979
Nazione #
US - Stati Uniti d'America 488
SG - Singapore 79
BR - Brasile 42
CN - Cina 41
HK - Hong Kong 36
IT - Italia 35
DE - Germania 23
SE - Svezia 18
VN - Vietnam 16
GB - Regno Unito 12
FI - Finlandia 11
PL - Polonia 11
NL - Olanda 10
FR - Francia 8
RU - Federazione Russa 7
AT - Austria 6
IN - India 6
TR - Turchia 5
AR - Argentina 4
KR - Corea 4
XK - ???statistics.table.value.countryCode.XK??? 4
BD - Bangladesh 3
CO - Colombia 3
CY - Cipro 3
IQ - Iraq 3
JO - Giordania 3
LV - Lettonia 3
MX - Messico 3
AD - Andorra 2
BE - Belgio 2
CG - Congo 2
CH - Svizzera 2
CM - Camerun 2
DJ - Gibuti 2
ES - Italia 2
GE - Georgia 2
GF - Guiana Francese 2
GM - Gambi 2
GN - Guinea 2
HR - Croazia 2
ID - Indonesia 2
JP - Giappone 2
LT - Lituania 2
PA - Panama 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
ZA - Sudafrica 2
ZM - Zambia 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AI - Anguilla 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
CA - Canada 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CU - Cuba 1
CV - Capo Verde 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
GT - Guatemala 1
HU - Ungheria 1
IE - Irlanda 1
IR - Iran 1
IS - Islanda 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LY - Libia 1
MA - Marocco 1
MG - Madagascar 1
MR - Mauritania 1
MY - Malesia 1
NA - Namibia 1
NE - Niger 1
NG - Nigeria 1
NI - Nicaragua 1
PF - Polinesia Francese 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
RE - Reunion 1
RS - Serbia 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SO - Somalia 1
TL - Timor Orientale 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
TZ - Tanzania 1
UG - Uganda 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
YT - Mayotte 1
Totale 979
Città #
Fairfield 82
Chandler 68
Ashburn 47
Singapore 44
Hong Kong 34
Santa Clara 29
Cambridge 23
Woodbridge 23
Houston 21
Padova 17
Beijing 12
San Diego 11
Bytom 10
Helsinki 10
Seattle 10
Boardman 9
Medford 9
Princeton 9
Ann Arbor 8
Des Moines 8
New York 8
Wilmington 8
Ho Chi Minh City 7
Los Angeles 7
Columbus 6
Roxbury 6
Hefei 5
Chicago 4
Falkenstein 4
São Paulo 4
Amman 3
London 3
Munich 3
Nuremberg 3
Ogden 3
Pune 3
Riga 3
Seoul 3
Amsterdam 2
Asunción 2
Belluno 2
Brasília 2
Brazzaville 2
Cayenne 2
Conakry 2
Djibouti 2
Duncan 2
Hounslow 2
Istanbul 2
Lima 2
Lusaka 2
Naaldwijk 2
Nicosia 2
Pignone 2
Portland 2
Pristina 2
Split 2
Tbilisi 2
Tokyo 2
Aalst 1
Abidjan 1
Afogados da Ingazeira 1
Alvorada 1
Andorra la Vella 1
Ankara 1
Antananarivo 1
Anápolis 1
Araras 1
Aveiro 1
Baghdad 1
Banjul 1
Barrackpore 1
Belo Horizonte 1
Belém 1
Benghazi 1
Bishkek 1
Blumenau 1
Bom Jardim 1
Botucatu 1
Brownsville 1
Brøndby 1
Buffalo 1
Burnaby 1
Busan 1
Bắc Giang 1
Cabrobó 1
Caicedonia 1
Caldas Novas 1
Camberley 1
Campo Belo 1
Canguaretama 1
Canoas 1
Catamarca 1
Charlotte 1
Chennai 1
Chicago Heights 1
Chinandega 1
Cúcuta 1
Dakar 1
Dallas 1
Totale 650
Nome #
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 134
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 130
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 123
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 118
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 115
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 115
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 99
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience 86
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report 73
Totale 993
Categoria #
all - tutte 4.752
article - articoli 4.752
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.504


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202167 0 0 0 0 0 31 9 2 7 3 1 14
2021/2022225 9 24 41 4 15 35 30 6 8 10 12 31
2022/2023121 23 19 3 17 10 11 1 9 21 4 3 0
2023/202485 11 9 14 7 7 14 5 1 4 3 5 5
2024/2025279 0 12 21 11 41 7 3 37 17 8 50 72
2025/2026216 56 90 70 0 0 0 0 0 0 0 0 0
Totale 993